A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

DOI

  • Mohammed Eslam, University of Sydney
  • ,
  • Philip N. Newsome, University Hospitals Birmingham NHS Foundation Trust
  • ,
  • Shiv K. Sarin, Institute of Liver and Biliary Sciences
  • ,
  • Quentin M. Anstee, Newcastle University
  • ,
  • Giovanni Targher, University and Azienda Ospedaliera Universitaria Integrata of Verona
  • ,
  • Manuel Romero-Gomez, Hospital Universitario Virgen del Rocio
  • ,
  • Shira Zelber-Sagi, University of Haifa
  • ,
  • Vincent Wai-Sun Wong, Chinese University of Hong Kong
  • ,
  • Jean François Dufour, University of Bern
  • ,
  • Jörn M. Schattenberg, Johannes Gutenberg University Mainz
  • ,
  • Takumi Kawaguchi, Kurume University
  • ,
  • Marco Arrese, Pontificia Universidad Catolica de Chile
  • ,
  • Luca Valenti, University of Milan
  • ,
  • Gamal Shiha, Mansoura University
  • ,
  • Claudio Tiribelli, Italian Liver Foundation
  • ,
  • Hannele Yki-Järvinen, Minerva Foundation Institute for Medical Research Helsinki
  • ,
  • Jian Gao Fan, Shanghai Jiao Tong University
  • ,
  • Henning Grønbæk
  • Yusuf Yilmaz, Marmara University
  • ,
  • Helena Cortez-Pinto, University of Lisbon
  • ,
  • Claudia P. Oliveira, Universidade de Sao Paulo
  • ,
  • Pierre Bedossa, Paris Descartes University
  • ,
  • Leon A. Adams, University of Western Australia
  • ,
  • Ming Hua Zheng, The First Affiliated Hospital of Wenzhou Medical University
  • ,
  • Yasser Fouad, Minia University
  • ,
  • Wah Kheong Chan, University of Malaya
  • ,
  • Nahum Mendez-Sanchez, Universidad Nacional Autónoma de México
  • ,
  • Sang Hoon Ahn, Yonsei University
  • ,
  • Laurent Castera, Paris Descartes University
  • ,
  • Elisabetta Bugianesi, University of Turin
  • ,
  • Vlad Ratziu, Sorbonne Université
  • ,
  • Jacob George, University of Sydney

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.

OriginalsprogEngelsk
BogserieJournal of Hepatology
Vol/bind73
Nummer1
Sider (fra-til)202-209
Antal sider8
ISSN0168-8278
DOI
StatusUdgivet - 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 194399734